Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia
Publication date :
14 August 2018
Journal title :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Publisher :
American Chemical Society, United States - District of Columbia
Zou, Y.-R.; Kottmann, A. H.; Kuroda, M.; Taniuchi, I.; Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393, 595-599, 10.1038/31269
Tran, P. B.; Miller, R. J. Chemokine receptors: signposts to brain development and disease. Nat. Rev. Neurosci. 2003, 4, 444-455, 10.1038/nrn1116
Fernandez, E. J.; Lolis, E. Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 469-499, 10.1146/annurev.pharmtox.42.091901.115838
Mantovani, A. The chemokine system: redundancy for robust outputs. Immunol. Today 1999, 20, 254-257, 10.1016/S0167-5699(99)01469-3
Johnson, Z.; Schwarz, M.; Power, C. A.; Wells, T. N. C.; Proudfoot, A. E. I. Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol. 2005, 26, 268-274, 10.1016/j.it.2005.03.001
Moser, B.; Willimann, K. Chemokines: role in inflammation and immune surveillance. Ann. Rheum. Dis. 2004, 63, ii84-ii89, 10.1136/ard.2004.028316
Godessart, N.; Kunkel, S. L. Chemokines in autoimmune disease. Curr. Opin. Immunol. 2001, 13, 670-675, 10.1016/S0952-7915(01)00277-1
Lazennec, G.; Richmond, A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16, 133-144, 10.1016/j.molmed.2010.01.003
Balkwill, F. R. The chemokine system and cancer. J. Pathol. 2012, 226, 148-157, 10.1002/path.3029
Koenen, R. R.; Weber, C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discovery 2010, 9, 141-153, 10.1038/nrd3048
Braunersreuther, V.; Mach, F.; Steffens, S. The specific role of chemokines in atherosclerosis. Thromb. Haemostasis 2007, 97, 714-721, 10.1160/TH07-01-0036
Wenzel, J.; Henze, S.; Worenkamper, E.; Basner-Tschakarjan, E.; Sokolowska-Wojdylo, M.; Steitz, J.; Bieber, T.; Tuting, T. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J. Invest. Dermatol. 2005, 124, 1241-1248, 10.1111/j.0022-202X.2005.23755.x
Bendall, L. Chemokines and their receptors in disease. Histol. Histopathol. 2005, 20, 907-926
Zipp, F.; Hartung, H. P.; Hillert, J.; Schimrigk, S.; Trebst, C.; Stangel, M.; Infante-Duarte, C.; Jakobs, P.; Wolf, C.; Sandbrink, R.; Pohl, C.; Filippi, M. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006, 67, 1880-1883, 10.1212/01.wnl.0000244420.68037.86
Brown, M. F.; Bahnck, K. B.; Blumberg, L. C.; Brissette, W. H.; Burrell, S. A.; Driscoll, J. P.; Fedeles, F.; Fisher, M. B.; Foti, R. S.; Gladue, R. P.; Guzman-Martinez, A.; Hayward, M. M.; Lira, P. D.; Lillie, B. M.; Lu, Y.; Lundquist, G. D.; McElroy, E. B.; McGlynn, M. A.; Paradis, T. J.; Poss, C. S.; Roache, J. H.; Shavnya, A.; Shepard, R. M.; Trevena, K. A.; Tylaska, L. A. Piperazinyl CCR1 antagonists - optimization of human liver microsome stability. Bioorg. Med. Chem. Lett. 2007, 17, 3109-3112, 10.1016/j.bmcl.2007.03.037
Johnson, M.; Li, A. R.; Liu, J.; Fu, Z.; Zhu, L.; Miao, S.; Wang, X.; Xu, Q.; Huang, A.; Marcus, A.; Xu, F.; Ebsworth, K.; Sablan, E.; Danao, J.; Kumer, J.; Dairaghi, D.; Lawrence, C.; Sullivan, T.; Tonn, G.; Schall, T.; Collins, T.; Medina, J. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg. Med. Chem. Lett. 2007, 17, 3339-3343, 10.1016/j.bmcl.2007.03.106
Horuk, R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discovery 2009, 8, 23-33, 10.1038/nrd2734
Hachet-Haas, M.; Balabanian, K.; Rohmer, F.; Pons, F.; Franchet, C.; Lecat, S.; Chow, K. Y.; Dagher, R.; Gizzi, P.; Didier, B.; Lagane, B.; Kellenberger, E.; Bonnet, D.; Baleux, F.; Haiech, J.; Parmentier, M.; Frossard, N.; Arenzana-Seisdedos, F.; Hibert, M.; Galzi, J. L. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J. Biol. Chem. 2008, 283, 23189-23199, 10.1074/jbc.M803947200
Balabanian, K.; Brotin, E.; Biajoux, V.; Bouchet-Delbos, L.; Lainey, E.; Fenneteau, O.; Bonnet, D.; Fiette, L.; Emilie, D.; Bachelerie, F. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood 2012, 119, 5722-5730, 10.1182/blood-2012-01-403378
Romain, B.; Hachet-Haas, M.; Rohr, S.; Brigand, C.; Galzi, J. L.; Gaub, M. P.; Pencreach, E.; Guenot, D. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol. Cancer 2014, 13, 58, 10.1186/1476-4598-13-58
Gasparik, V.; Daubeuf, F.; Hachet-Haas, M.; Rohmer, F.; Gizzi, P.; Haiech, J.; Galzi, J. L.; Hibert, M.; Bonnet, D.; Frossard, N. Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand prevent inflammatory reactions in an asthma model in vivo. ACS Med. Chem. Lett. 2012, 3, 10-14, 10.1021/ml200017d
Daubeuf, F.; Hachet-Haas, M.; Gizzi, P.; Gasparik, V.; Bonnet, D.; Utard, V.; Hibert, M.; Frossard, N.; Galzi, J. L. An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice. J. Biol. Chem. 2013, 288, 11865-11876, 10.1074/jbc.M112.449348
Veldkamp, C. T.; Ziarek, J. J.; Peterson, F. C.; Chen, Y.; Volkman, B. F. Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. J. Am. Chem. Soc. 2010, 132, 7242-7243, 10.1021/ja1002263
Smith, E. W.; Liu, Y.; Getschman, A. E.; Peterson, F. C.; Ziarek, J. J.; Li, R. S.; Volkman, B. F.; Chen, Y. Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine. J. Med. Chem. 2014, 57, 9693-9699, 10.1021/jm501194p
Smith, E. W.; Nevins, A. M.; Qiao, Z.; Liu, Y.; Getschman, A. E.; Vankayala, S. L.; Kemp, M. T.; Peterson, F. C.; Li, R. S.; Volkman, B. F.; Chen, Y. Structure-based identification of novel ligands targeting multiple sites within a chemokine-G-protein-coupled-receptor interface. J. Med. Chem. 2016, 59, 4342-4351, 10.1021/acs.jmedchem.5b02042
Weisberg, E. L.; Sattler, M.; Azab, A. K.; Eulberg, D.; Kruschinski, A.; Manley, P. W.; Stone, R.; Griffin, J. D. Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget 2017, 8, 109973-109984, 10.18632/oncotarget.22409
Rucker, H.; Al-Rifai, N.; Rascle, A.; Gottfried, E.; Brodziak-Jarosz, L.; Gerhauser, C.; Dick, T. P.; Amslinger, S. Enhancing the anti-inflammatory activity of chalcones by tuning the Michael acceptor site. Org. Biomol. Chem. 2015, 13, 3040-3047, 10.1039/C4OB02301C
Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Befani, O.; Turini, P.; Ortuso, F.; Alcaro, S. Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors. J. Med. Chem. 2007, 50, 425-428, 10.1021/jm060868l
Maillet, E. L.; Pellegrini, N.; Valant, C.; Bucher, B.; Hibert, M.; Bourguignon, J. J.; Galzi, J. L. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 2007, 21, 2124-2134, 10.1096/fj.06-7683com
Valenzuela-Fernandez, A.; Palanche, T.; Amara, A.; Magerus, A.; Altmeyer, R.; Delaunay, T.; Virelizier, J. L.; Baleux, F.; Galzi, J. L.; Arenzana-Seisdedos, F. Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans. J. Biol. Chem. 2001, 276, 26550-26558, 10.1074/jbc.M100411200
Galzi, J.-L.; Haas, M.; Frossard, N.; Hibert, M. Why and how to find neutraligands targeting chemokines?. Drug Discovery Today: Technol. 2012, 9, e245-e251, 10.1016/j.ddtec.2012.03.005
Gould, S.; Scott, R. C. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem. Toxicol. 2005, 43, 1451-1459, 10.1016/j.fct.2005.03.007
Daubeuf, F.; Frossard, N. Acute asthma models to ovalbumin in the mouse. Curr. Protoc. Mouse Biol. 2011, 3, 31-37, 10.1002/9780470942390.mo120202
Daubeuf, F.; Frossard, N. Performing bronchoalveolar lavage in the mouse. Curr. Protoc. Mouse Biol. 2012, 2, 167-175, 10.1002/9780470942390.mo110201
Desaphy, J.; Azdimousa, K.; Kellenberger, E.; Rognan, D. Comparison and druggability prediction of protein-ligand binding sites from pharmacophore-annotated cavity shapes. J. Chem. Inf. Model. 2012, 52, 2287-2299, 10.1021/ci300184x
Korb, O.; Stutzle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J. Chem. Inf. Model. 2009, 49, 84-96, 10.1021/ci800298z
Jain, A. N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput.-Aided Mol. Des. 2007, 21, 281-306, 10.1007/s10822-007-9114-2
Schneider, N.; Lange, G.; Hindle, S.; Klein, R.; Rarey, M. A consistent description of HYdrogen bond and DEhydration energies in protein-ligand complexes: methods behind the HYDE scoring function. J. Comput.-Aided Mol. Des. 2013, 27, 15-29, 10.1007/s10822-012-9626-2
Abboud, D.; Daubeuf, F.; Do, Q. T.; Utard, V.; Villa, P.; Haiech, J.; Bonnet, D.; Hibert, M.; Bernard, P.; Galzi, J. L.; Frossard, N. A strategy to discover decoy chemokine ligands with an anti-inflammatory activity. Sci. Rep. 2015, 5, 2045-2322, 10.1038/srep14746
Lukacs, N. W.; Berlin, A.; Schols, D.; Skerlj, R. T.; Bridger, G. J. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol. 2002, 160, 1353-1360, 10.1016/S0002-9440(10)62562-X
Bietz, S.; Urbaczek, S.; Schulz, B.; Rarey, M. Protoss: a holistic approach to predict tautomers and protonation states in protein-ligand complexes. J. Cheminf. 2014, 6, 12, 10.1186/1758-2946-6-12